Novartis Investigative Site

Manila, National Capital Region 1003

0 studies enrolling now · 8 studies all time

What they study most

Acute Heart Failure, Acute Myocardial Infarction, Heart Failure With Reduced Ejection Fraction (HF-rEF), Hypertension, Primary Prevention of Atherosclerotic Cardiovascular Disease, Psoriatic Arthritis

Studies at this site

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF) — NO_LONGER_AVAILABLE
• Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis — Completed
• Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis — Completed
• Global Non-interventional Heart Failure Disease Registry — Stopped early
• Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) — Completed
• Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan — Completed